Announcements coming:
2024
FDA and Neuren to confirm endpoints and path forward for Pheland McDermid Syndrome - (Expect positive)
New Indications to be announced (Very Exciting - before Xmas Jon intimated quite clearly...)
Acadia update for Daybue in November (Expect Ok) - The recent circa 10% "miss" on targets by Daybue was the major or even sole reason for the recent share price drop. Neuren are stll "encouraged by growth ahead with Daybue"
Decision for Daybue from Cananda (Expect Positive)
Q1 2025
Acadia expect to file application for Daybue in Europe (Expect Positive)
Other 2591 indications meetings with FDA (PHS and Angelmans Syndrome) (Expect Positive)
Over $200 million in the bank and more coming to cover the costs of the above trials and bringing to production.
Also - Neuren are aiming to get through at least one Phase 3 trial with NNZ2591 on their own, before even considering partnering or takeover.
Announcements coming:2024 FDA and Neuren to confirm endpoints...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |